Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.90 USD
Change Today -0.09 / -3.01%
Volume 190.6K
CTIX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

cellceutix corp (CTIX) Snapshot

Open
$2.94
Previous Close
$2.99
Day High
$2.99
Day Low
$2.90
52 Week High
12/12/14 - $4.93
52 Week Low
04/25/14 - $1.59
Market Cap
340.5M
Average Volume 10 Days
234.8K
EPS TTM
$-0.11
Shares Outstanding
117.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLCEUTIX CORP (CTIX)

Related News

No related news articles were found.

cellceutix corp (CTIX) Related Businessweek News

No Related Businessweek News Found

cellceutix corp (CTIX) Details

Cellceutix Corporation, a clinical stage biopharmaceutical company, focuses on discovering and developing small molecule drugs to treat drug-resistant cancers, psoriasis, autism, and inflammatory diseases. Its flagship compounds include Kevetrin, an anti-cancer compound that is in Phase I clinical trial for the treatment of cancer; Prurisol, an anti-psoriasis drug candidate that has completed Phase I clinical trial; and Brilacidin, an antibiotic candidate for the treatment of diabetic foot ulcer infections, and other indications, such as ophthalmic and otitic infections, as well as for other skin infections and oral mucositis. The company’s preclinical stage compounds comprise KM 391 for the treatment of autism; KM 277 for the treatment of rheumatoid arthritis; KM 278 for the treatment of arthritis/asthma; KM 362 for the treatment of MS/ALS/Parkinson’s disease; KM-3174 for the treatment of cancer; and KM-732 for hypertensive emergency, as well as Delparantag, a synthetic small-molecule for the treatment of other diseases, including chronic obstructive pulmonary disease. In addition, its other product candidates include compounds active against other gram-negative bacterias, malaria, tuberculosis, biowarfare pathogens, and PolyCide antimicrobial biomaterials. The company was founded in 2007 and is headquartered in Beverly, Massachusetts.

9 Employees
Last Reported Date: 09/15/14
Founded in 2007

cellceutix corp (CTIX) Top Compensated Officers

Chairman, Chief Executive & Financial Officer...
Total Annual Compensation: $444.7K
President, Chief Scientific Officer and Direc...
Total Annual Compensation: $444.7K
Compensation as of Fiscal Year 2014.

cellceutix corp (CTIX) Key Developments

Cellceutix Corporation Mulls Acquisitions

Cellceutix Corporation (OTCPK:CTIX) is seeking acquisitions. Cellceutix Corporation has filed a Follow-on Equity Offering in the amount of $30.00 million and said "We may also use a portion of the net proceeds to pay off outstanding indebtedness and/or acquire or invest in complementary businesses, products and technologies. Although we have no specific agreements, commitments or understandings with respect to any acquisition other than those publicly disclosed, we evaluate acquisition opportunities and engage in related discussions with other companies from time to time and may use a portion of the proceeds from this offering in connection with one or more such acquisitions."

Cellceutix Corporation Announces Tenth Cohort in its Phase 1 Clinical Trial of Kevetrin

Cellceutix Corporation announced that the tenth cohort in the company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has been completed. Patients in the tenth cohort were treated with 450 mg/m2 of Kevetrin with no adverse events reported. The company has been advised that the tenth cohort is being included in the latest testing for the effect of Kevetrin on the biomarker p21, a key downstream protein and proxy for reactivation of the tumor suppressor protein p53. The data on p21 are expected to be received in mid-April. The company had several options on the table moving forward with the trial. After meeting with the trial's Principal Investigator and Cellceutix consultants, the Company has decided to take dosing even higher due to the wide bandwidth of Kevetrin and enroll an eleventh cohort. The Safety Committee will meet in the coming weeks to determine the new dosing level, which, theoretically, could be increased up to 100% in a bid to define the maximum tolerated dose of Kevetrin.

Cellceutix Corporation to Expand its Skin Product Pipeline

Cellceutix Corporation announced that it is expanding its dermatology pipeline to include novel Human Defense Protein (HDP) mimetics for the treatment of chronic skin conditions, such as acne vulgaris, rosacea, and hidradenitis suppurativa (HS). Recently conducted pre-clinical research supports these conditions as targets due to the robust antimicrobial and anti-inflammatory properties of Cellceutix's HDP mimetics. These are conditions for which there is no consistently effective treatment, as in the case of HS, or there is room to improve upon current therapies, as in acne vulgaris or rosacea. In these conditions, topical antibiotics have been used, with mixed or disappointing results, most likely due to a lack of anti-inflammatory activity in concert with an inability to treat bacteria, such as Propionibacterium acnes, that are growing increasingly resistant to current therapies. The HDP mimetics can overcome both hurdles: they have anti-inflammatory properties and they can kill key bacteria without promoting further resistance. The latter is important, because traditional antibiotics, when chronically used, are likely to promote resistance, whereas HDP mimetics, given their unique structure and mechanism of action, are unlikely to promote resistance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIX:US $2.90 USD -0.09

CTIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CTIX.
View Industry Companies
 

Industry Analysis

CTIX

Industry Average

Valuation CTIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 48.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLCEUTIX CORP, please visit www.cellceutix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.